Silexion Therapeutics Corp Stock Price, News & Analysis

Silexion Therapeutics (NASDAQ:SLXN) said company management will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 3, 2025 from 2:30–2:55pm ET at Florida Atlantic University Conference Center, Boca Raton, FL (Presentation Room 5).

Speakers include Ilan Hadar, CEO and Mirit Horenshtein-Hadar, CFO. Management will be available for one-on-one meetings by arrangement. A replay will be posted to Silexion's investor relations Events & Presentations page after the conference.

Silexion Therapeutics (NASDAQ: SLXN) completed two‑species toxicology studies for SIL204, its next‑generation siRNA therapy targeting mutated KRAS, which showed no systemic organ toxicity. The company said these results support planned regulatory submissions to Israel and Germany and keep Silexion on track to start a Phase 2/3 trial in locally advanced pancreatic cancer in Q2 2026. Preclinical data cited include broad in vitro KRAS mutant cell‑line growth inhibition and systemic anti‑tumor activity in pancreatic sites. Management noted a secured CRO partner and an integrated intratumoral plus systemic dosing approach as next steps toward clinical development.

Silexion Therapeutics (NASDAQ: SLXN) reported Q3 2025 results and a business update on Nov 12, 2025. The company raised approximately $9.5 million in Q3, increasing cash to $9.2 million as of Sept 30, 2025, and shareholders' equity to $7.0 million. Silexion selected AMS Advanced Medical Services as CRO and remains on track to file regulatory submissions in Israel in Q4 2025 and in Germany/EU in Q1 2026, targeting Phase 2/3 initiation in H1 2026. New preclinical data show SIL204 killed cancer cells across five KRAS-driven cancer types and eight mutations, including first evidence in gastric cancer. Nasdaq listing compliance was regained on Sept 23, 2025.

Silexion Therapeutics (NASDAQ:SLXN) has announced breakthrough preclinical data for its pan-KRAS inhibitor SIL204, demonstrating exceptional efficacy across multiple cancer types. The drug achieved 83.5% to 99.7% inhibition in eleven human cell lines across 5 different organ cancer sites.

Key highlights include the first evidence of gastric cancer activity, with 89.2% inhibition in the SNU-601 cell line, and remarkable efficacy in lung cancer cells showing up to 99.7% inhibition. The drug demonstrated activity against eight KRAS mutations (G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D) at nanomolar concentrations.

Silexion plans to advance SIL204 to Phase 2/3 clinical trials in H1 2026, with regulatory submissions scheduled for Q4 2025 in Israel and Q1 2026 in the EU.

Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, has regained compliance with Nasdaq's listing requirements. The company has met both the minimum bid price requirement of $1.00 per share and the minimum shareholders' equity requirement of $2.5 million.

The company is preparing for Phase 2/3 clinical trials of its SIL204 therapy, scheduled for the first half of 2026. Recent preclinical data showed promising results with up to 97% inhibition rates across multiple KRAS-driven cancer types. Silexion has also established a strategic CRO collaboration to advance its clinical development strategy.

Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on RNA interference therapies for KRAS-driven cancers, has announced the pricing of a $6.0 million public offering. The offering includes 1,500,000 ordinary shares (or equivalents) with accompanying series A and B warrants at $4.00 per share.

The offering includes series A warrants with a 5-year term and series B warrants with a 12-month term, both with a $4.00 exercise price. H.C. Wainwright & Co. is serving as the exclusive placement agent. The proceeds will support pre-clinical studies and general corporate purposes, with closing expected around September 12, 2025.

Silexion Therapeutics (NASDAQ:SLXN) announced positive preclinical data for its pancreatic cancer drug SIL204. The study demonstrated that subcutaneously administered SIL204 successfully reached major pancreatic cancer metastatic sites and showed anti-tumor activity.

Key findings include successful drug distribution to liver, peritoneum, and lung following a single subcutaneous injection at 5mg/mouse, with statistically significant reductions (p<0.01) in tumor burden observed in the peritoneum, lung, and intestine. The results validate the systemic component of Silexion's dual-route administration strategy.

The company remains on track to initiate Phase 2/3 clinical trials in H1 2026, with regulatory submissions planned for Q4 2025 and Q1 2026.

Silexion Therapeutics (NASDAQ:SLXN) has selected AMS Advanced Medical Services GmbH as its Contract Research Organization (CRO) to support upcoming Phase 2/3 clinical trials for SIL204, their RNA interference therapy targeting KRAS-driven cancers.

The partnership follows impressive preclinical results showing up to 97% inhibition in pancreatic cancer cells, ~90% inhibition in colorectal cancer cells, and significant activity in lung cancer cell lines. SIL204 has demonstrated effectiveness against multiple KRAS mutations including G12D, G12V, G12R, Q61H, and G13D.

Regulatory submissions are planned for Q4 2025 (Israel) and Q1 2026 (EU), with Phase 2/3 trials expected to commence in H1 2026. The trials will evaluate SIL204's dual-route administration approach in locally advanced pancreatic cancer patients.

Silexion Therapeutics (NASDAQ:SLXN), a clinical-stage biotech company focused on RNA interference therapies for KRAS-driven cancers, will present at the 27th Annual H.C. Wainwright Global Investment Conference. The presentation is scheduled for September 10, 2025, at 2:00 PM ET at the Lotte New York Palace Hotel.

The company has uploaded an updated corporate presentation to their website's investor section. Management will be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.